Surrozen Initiates Dosing of First Patient in Phase 1b Clinical Trial of SZN-043 for Severe Alcohol-Associated Hepatitis
SZN-043 is a novel hepatocyte-specific R-spondin mimetic bispecific fusion protein targeting ASGR1Anticipate potential proof-of-concept data available in the first half of 2025 SOUTH SAN FRANSCISO, Calif., June 04, 2024 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a company pioneering targeted therapeutics that selectively activate the Wnt pathway for tissue repair and regeneration, today announced that the first patient has been dosed in its Phase 1b clinical
Read More
“We are gaining momentum in our SZN-043 clinical trial program in severe alcohol-associated hepatitis and anticipate that proof-of-concept data may be available in the first half of 2025.”
Craig Parker, President and Chief Executive Officer of Surrozen
“Severe alcohol-associated hepatitis remains an unmet medical need with a very high mortality and no improvement in survival for more than 50 years. I am very excited about the potential for SZN-043 to offer a meaningful clinical benefit to these patients.”
Edward Gane MBCHB, MD, FRACP, MNZM, Professor of Medicine at the University of Auckland, New Zealand, Hepatologist and Deputy Director of the New Zealand Liver Unit at the Auckland City Hospital